Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393388 · ClinicalTrials.gov registry record
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
A clinical trial of Alzheimer Disease and Cognitive Decline, sponsored by University of Pennsylvania.
- Active
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT05393388: Active study of Alzheimer Disease and Cognitive Decline, sponsored by University of Pennsylvania.
NCT05393388 is a study of Alzheimer Disease and Cognitive Decline that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 111 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05393388, a study of Alzheimer Disease and Cognitive Decline, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit for PET imaging, but all subjects will be followed annually as part of their participation in the ABCD2 study. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical Alzheimer's Disease.
Primary Outcome
A quantitative measurement of \[18F\]AV-1451(standardized value uptake ratio - SUVR) within the medial temporal lobe (MTL).from PET/CT
Conditions Studied
Interventions
- DRUG [18F]AV-1451
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Penn Memory Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-07-06 |
| Est. Completion | 2027-05 |
What the registry record for NCT05393388 still lists
NCT05393388 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]AV-1451 is the first listed.
NCT05393388 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05393388 about?
NCT05393388 is a clinical study titled "Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study". We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit...
What is the current status of trial NCT05393388?
This trial is currently active not recruiting. The enrollment target is 111 participants. The study started on 2022-07-06. Estimated completion is 2027-05.
What conditions does trial NCT05393388 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Decline.
What interventions are being tested in trial NCT05393388?
The interventions under investigation include: [18F]AV-1451 (DRUG).
Who is sponsoring clinical trial NCT05393388?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05393388 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05393388's enrollment target sits among peer trials
111 146th of 306 higher than 161 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI